Show/Hide Menu

Proprietary Portfolio

The continued success of its partnered discovery segment provides MorphoSys with the adequate resources to channel substantial investment into proprietary R&D. Its in-house development organization focuses on the development of promising therapeutic antibody candidates in the area of inflammation and oncology. Learn more about the our programs which are in clinical evaluation:

MorphoSys is committed to expanding its proprietary portfolio. We believe that each program has a substantial therapeutic potential.

Dr. Arndt Schottelius
Chief Development Officer

Clinical Programs

MOR208

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
Further Information

MOR202

In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.
Further Information

MOR103/GSK3196165

MOR103 (GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases.
Further Information

MOR209/ES414

MOR209/ES414 is a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer. The immunotherapeutic protein activates the patients’ T-cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA), an antigen commonly overexpressed in this tumor.
Further Information

MOR106

MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory diseases.
Further Information